spacer
home > ebr > autumn 2017 > editors letter
PUBLICATIONS
European Biopharmaceutical Review

Editors Letter

Since our last edition of EBR went to print, there have been significant innovations in new medicines, including those for heart disease, with the anti-inflammatory canakinumab (anti-interleukin-1 beta/ ACZ885) described in the media as the ‘biggest breakthrough in cardiovascular medicine since statins...’ (1). Additionally, the milestone approval of Kymrhia (tisagenlecleucel) in the US, the first chimerical antigen receptor (CAR) T-cell therapy for blood cancers, heralds “a new frontier” of medicine, according to Scott Gottlieb at the FDA (2). These are exciting new next-generation biopharmaceuticals, biological and advanced therapy medicinal products (ATMPs), the latter being the ultimate in personalised medicine, generated from the patient’s own lymphocytes.

A key component of the successful and, arguably, much more established drug development pathways for small molecules that require first pass liver metabolism is an understanding of their metabolism and kinetic properties, from both a safety and efficacy perspective. Dr Richard Weaver FRSC of XenoGesis Ltd highlights the importance of early expertise in drug metabolism and pharmacokinetics and absorption distribution metabolism elimination properties for development pathways. Meanwhile, Optibrium Ltd’s Matthew Segall looks at the role of mathematical and computational modelling of cytochrome P450 interactions.

For any therapy employing human tissue systems at the preclinical phase of development – such as the 3D organoid introduced by QGel’s Dr Colin Sanctuary or the tailored, precision medicine tissue systems the Glasgow-based Aridhia, ReproCELL Europe and Stratified Medicine Scotland team are continuing to pioneer – can better predict drug response outcomes in terms of safety and efficacy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Deborah O’Neil, Chief Executive and Scientific Officer, NovaBiotics Ltd
spacer
Dr Deborah O’Neil
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Digital Health and Wearables

• Datwyler uses strategic partnerships to develop new solutions in the fields of wearables and digital health. • The company’s health care offering is always designed towards improving the comfort of patients during treatment. • The product portfolio and innovative healthcare solutions will be presented at several important trade fairs of the medical sector.
More info >>

White Papers

Translating Cancer Genomics Into A Personalised Approach For Cancer Patients

PRA Health Sciences (PRA)

Over the past few decades, the approach to prevention, diagnosis and treatment of cancer has radically shifted from organ-based to morphology-based and most recently, to genetics-based. Personalized or precision medicine (tailoring a treatment for a patient’s particular disease at a precise time point) is being performed every day at different levels in the clinical setting.
More info >>

 
Industry Events

BioTrinity 2019

30 April - 1 May 2019, etc.venues 155 Bishopsgate, London EC2M 3YD

BioTrinity 2019 is taking place from the 30th April – 1stMay at etc.venues 155 Bishopsgatein London. Now in its 13th year, BioTrinity remains the leading Life Sciences Biopartnering and Investment conference in Europe, and generates unrivalled opportunities for life science companies, academics, investors, and major pharmaceutical players to come together to do deals and establish collaborations.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement